Andrew Green Sells AORT Shares in Planned Transaction

Andrew Green, SVP at AORT, sold 44,001 shares on June 11, 2026, in a planned sale.

Written by EarningsIQ · Published Jun 15, 2026, 12:01 PM EDT · Updated Jun 15, 2026, 5:05 PM EDT

Key Points

Andrew Green, SVP of Regulatory and Quality at AORT, sold 44,001 shares on June 11, 2026, at an average price of $20.70, totaling $910,662.
Shares of AORT traded near $20.35, with active institutional interest from peers like BlackRock and FMR LLC.
Analysts have maintained a positive outlook on AORT, with firms like Citizens and Needham reiterating 'buy' ratings and targets up to $58.

Andrew Green, Senior Vice President of Regulatory and Quality at AORT, sold 44,001 shares of the company on June 11, 2026. This planned transaction was executed at an average price of $20.70 per share, amounting to approximately $910,662.

Other Institutional Activity in AORT

Several institutional investors have been active in AORT recently. BlackRock, Inc. increased its holdings by 106,735 shares, bringing its total to 6,474,854 shares valued at about $237.1 million. FMR LLC also added 41,560 shares, ending with 2,583,427 shares worth around $94.6 million. Meanwhile, Nomura Asset Management International Inc. reduced its position by 157,325 shares, holding 2,456,146 shares valued at $89.9 million. Morgan Stanley added 12,552 shares, totaling 2,269,294 shares worth $83.1 million. Vanguard Capital Management LLC initiated a position with 1,952,008 shares valued at $71.5 million.

AORT Stock Snapshot

Shares of AORT were trading near $20.35 recently. The company has attracted significant institutional interest, as evidenced by recent activities from major funds.

Insider Buying and Selling at Artivion, Inc.

Alongside Andrew Green's sale, other notable insider activity includes Anthony Semedo, who executed several transactions in May and June 2026. On June 2, Semedo sold 6,325 shares, while on May 18, he bought 7,576 shares.

Analysts Set New Price Targets

Analysts have shown a strong interest in AORT. On May 8, 2026, Citizens maintained a 'buy' rating with a $48 target, while Needham upheld its 'buy' rating with a $44 target. Earlier, on April 10, 2026, Ladenburg Thalmann upgraded AORT to a 'buy' with a $42 target.

Bottom Line

Andrew Green's recent sale of AORT shares is part of a planned transaction, reflecting ongoing insider activity. Investors often track such moves closely to gauge insider sentiment. Institutional investors have shown varied interest, with some increasing their stakes. Analyst sentiment remains positive, with multiple firms maintaining or upgrading their ratings. As always, these insights are based on past filings and may not reflect current positions.